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Abstract
Background: Atrial fibrillation is the most common arrhythmia of the heart with a prevalence of approximately 2%
in the western world. Atrial flutter, another arrhythmia, occurs less often with an incidence of approximately 200,000
new patients per year in the USA. Patients with atrial fibrillation and atrial flutter have an increased risk of death
and morbidities. In the management of atrial fibrillation and atrial flutter, it is often necessary to use medical
interventions to lower the heart rate. Lowering the heart rate may theoretically prevent the development of heart
failure and tachycardia-mediated cardiomyopathy. The evidence on the benefits and harms of digoxin compared
with placebo or with other medical interventions is unclear. This protocol for a systematic review aims at
identifying the beneficial and harmful effects of digoxin compared with placebo, no intervention, or with other
medical interventions for atrial fibrillation and atrial flutter.
Methods: This protocol for a systematic review was conducted following the recommendations of Cochrane and
the eight-step assessment procedure suggested by Jakobsen and colleagues. We plan to include all relevant
randomised clinical trials comparing digoxin with placebo, no intervention, or with other medical interventions. We
plan to search the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS, Science
Citation Index Expanded on Web of Science, and BIOSIS to identify relevant trials. Any eligible trial will be assessed
and classified as either at high risk of bias or low risk of bias, and our primary conclusions will be based on trials
with low risk of bias. We will perform our meta-analyses of the extracted data using Review Manager 5.3 and Trial
Sequential Analysis ver. 0.9.5.5 beta. For both our primary and secondary outcomes, we will create a ‘Summary of
Findings’ table based on GRADE assessments of the quality of the evidence.
Discussion: The results of this systematic review have the potential to benefit millions of patients worldwide as
well as healthcare economy.
Systematic review registration: PROSPERO CRD42016052935
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Background
Atrial fibrillation is the most common arrhythmia of the
heart with a prevalence of approximately 2% in the
western world [1, 2]. Atrial flutter, another arrhythmia,
occurs less often with an incidence of approximately
200,000 new patients per year in the USA [3]. The
prevalence of both atrial fibrillation and atrial flutter are
increasing possibly because of a greater life expectancy
in the general population, an increased prevalence of
risk factors for atrial fibrillation and atrial flutter, and an
improved ability to suspect and diagnose the arrhyth-
mias [1, 4, 5]. Atrial fibrillation and atrial flutter are as-
sociated with an increased risk of death and morbidities
[6–12]. The risks of both cerebral stroke and heart fail-
ure are increased nearly fivefold in patients with atrial
fibrillation and atrial flutter, and an estimated 20% of
every stroke may be due to atrial fibrillation [6–11].
Atrial fibrillation and atrial flutter also have a significant
impact on healthcare costs and account for approxi-
mately 1% of the National Health Service budget in the
UK and approximately 26 billion dollars of annual
expenses in the USA [13, 14].
Definition and classification
The atriums of the heart receive blood returning from
the body and pump it further ahead to the ventricles.
Atrial fibrillation and atrial flutter are defined as abnor-
mal heart rhythms that arise from improper electrical
activity of the heart which lead to ineffective mechanical
contraction [15–17]. The ineffective mechanical contrac-
tion stresses the muscle cells of the heart which over
time may cause heart failure [18, 19]. Persistent rapid
rates can also cause or worsen a tachycardia-mediated
cardiomyopathy [20].
Atrial fibrillation and atrial flutter can be asymptom-
atic or lead to symptoms such as palpitations, dyspnoea,
and dizziness [21]. Atrial fibrillation may be diagnosed
using an electrocardiogram as (1) irregular R-R intervals
(when atrioventricular conduction is present), (2)
absence of distinct repeating P-waves, and (3) irregular
atrial activity [16, 17]. Atrial flutter may be diagnosed
using an electrocardiogram as characteristic flutter
waves (F-waves) at a regular atrial rate of 250 to 350
beats per minute. The flutter waves may resemble P-
waves or have a ‘saw-tooth’ shape [22].
Atrial fibrillation may either be non-valvular or valvu-
lar, where the latter form is characterised by rheumatic
mitral stenosis, mechanical heart valve, tissue heart
valve, or mitral valve repair [1]. However, the definition
of the terms non-valvular and valvular lacks consistency
in both trials and guidelines [23, 24]. A paper has pro-
posed a new term ‘mechanical and rheumatic mitral
valvular atrial fibrillation’, as the authors report that only
mechanical valves and mitral stenosis have special needs
in regard to antithrombotic treatment [24].
The development of atrial fibrillation is associated with
various risk factors, e.g. ageing, obesity, smoking, hyper-
tension, diabetes, and other cardiac diseases (valvular or
other structural heart diseases) [17, 25]. The develop-
ment of atrial flutter is presumably associated with pro-
longed PR interval on an electrocardiogram and some of
the same risk factors as atrial fibrillation [8]. However, it
has not been demonstrated that atrial flutter is associ-
ated with either obesity, diabetes, hypertension, or valvu-
lar heart disease [8]. Both atrial fibrillation and atrial
flutter may also occur in patients with no risk factors
(so-called lone atrial fibrillation or lone atrial flutter) [3].
Based on the duration of the arrhythmia, atrial fibrilla-
tion may be divided into five different forms [15–17]:
 Recent-onset atrial fibrillation
 Paroxysmal atrial fibrillation
 Persistent atrial fibrillation
 Long-standing persistent atrial fibrillation
 Permanent atrial fibrillation
Based on the re-entrant circuit, atrial flutter may be
divided into two different forms:
 Typical atrial flutter is a macro-reentrant atrial
tachycardia that can be subdivided based on the
rotation of the circuit to counterclockwise atrial
flutter (90% of patients) or clockwise atrial flutter
(10% of patients) [26].
 Atypical atrial flutter is defined as any atrial
tachycardia with an electrocardiogram pattern of
continuous undulation of the atrial complex,
different from typical atrial flutter, at a rate of ≥240
beats per minute [26].
Pathophysiology
The pathogenesis of atrial fibrillation is thought to be an
interaction between a trigger for initiation and an abnor-
mal tissue substrate for maintenance [25].
The trigger for initiation is often a rapidly firing focus
most often located in the left atrium and the proximal
parts of the pulmonary veins [27]. The abnormal tissue
substrate for maintenance is often a result of an under-
lying heart disease like coronary heart disease, valvular
heart disease, cardiomyopathies, or heart failure [16].
The pathogenesis of the abnormal tissue substrate is
induced by inflammation [28], fibrosis [29], or hyper-
trophy [30].
Electric remodelling, such as refractory period short-
ening, occurs after a period of continuous atrial fibrilla-
tion that further facilitates atrial fibrillation, i.e. atrial
fibrillation leads to atrial fibrillation [30, 31].
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Nevertheless, the electric remodelling is often reversible
if sinus rhythm is restored, though it can become
permanent if atrial fibrillation persists [31].
Atrial flutter is classified as a macro-reentrant tachycar-
dia. The macro-reentrant tachycardia occurs when an
electrical impulse recurrently moves in a self-perpetuating
circuit within the heart, rather than moving from one end
of the heart to the other and terminating [26].
Antithrombotic treatment
As mentioned (see the ‘Background’ section), the risk of
stroke is increased nearly fivefold in patients with atrial
fibrillation and atrial flutter [10]. Antithrombotic treat-
ment is necessary to reduce the risk of stroke in high-
risk patients with atrial fibrillation and atrial flutter,
regardless of the management strategy of the heart dis-
ease [16]. The risk of stroke in patients with atrial fibril-
lation and atrial flutter can be estimated by the
CHA2DS2-VASc score [32], while the risk of bleeding
can be estimated by the HAS-BLED score [33]. Com-
bined, these scores may help the physician determine
the patient’s need for antithrombotic treatment [16].
Antithrombotic drugs aim at reducing the formation
of thrombi by affecting different clotting processes.
Depending on the mechanism, the drugs are divided into
either anticoagulants or antiplatelet drugs. The classifi-
cation, mechanism, and examples of anticoagulants and
antiplatelet drugs are summarised in Table 1.
The comparative efficacy and safety between anticoag-
ulants and antiplatelet drugs has been assessed. Two
systematic reviews have shown that warfarin (vitamin K-
dependent antagonist) and apixaban (non-vitamin K-
dependent antagonist) are both superior to antiplatelet
drugs for preventing stroke, with a comparable rate of
major bleeding and intracranial haemorrhage [34, 35].
The comparative benefits and harms between warfarin
and non-vitamin K-dependent antagonists has been
assessed. Ruff et al. showed in a systematic review that
the non-vitamin K-dependent antagonists compared
with warfarin significantly reduced the risk of all-cause
mortality by 10%, stroke by 19%, and intracranial haem-
orrhage by 52% [36]. However, the risk of gastrointes-
tinal bleeding was increased by 25% by the non-vitamin
K-dependent antagonists [36].
Description of the intervention
As mentioned (see the ‘Background’ section), atrial fibrilla-
tion and atrial flutter cause the atriums and ventricles to
beat rapidly and irregularly which stresses the muscle cells
of the heart. An intervention to control the heart rate,
mainly digoxin, beta blockers, non-dihydropyridine cal-
cium channel blockers, amiodarone, or sotalol, is therefore
often necessary to reduce the heart rate and consequently
prevent excessive tachycardia and limit symptoms in
nearly all patients with atrial fibrillation and atrial flutter
[16, 22]. Lowering the heart rate might also theoretically
prevent the development of heart failure and tachycardia-
mediated cardiomyopathy [18, 20, 37].
The drugs used as treatment for atrial fibrillation and
atrial flutter are classified according to two different
classifications: the Vaughan Williams classification and
the Sicilian Gambit classification.
 The Vaughan Williams classification classifies the
drugs in five different classes according to their
general effect [38]. The Vaughan Williams
classification is summarised in Table 2.
 The Sicilian Gambit classification places a greater
focus on the underlying mechanism of the drugs
and classifies each drug according to the effects on
bio-cellular channels, receptors, and pumps. We will
not describe this classification in detail but refer
to the work by the European Society of
Cardiology [39].
We will in this systematic review use the Vaughan
Williams classification as it is the most commonly used
classification.
Digoxin
Digoxin (Vaughan Williams class V) is thought to in-
crease the contractility of the heart (inotropic effect) and
decreases the heart rate (chronotropic effect). The con-
tractility of the heart is increased by inhibiting the Na
+/K+ ATPase. The inhibited Na+/K+ ATPase results in a
higher concentration of intracellular calcium which leads
to an increase in the left ventricular systolic function
Table 1 The classification, mechanism, and examples of
anticoagulants and antiplatelet drugs
Class Mechanism Examples
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[40]. The heart rate is decreased by inducing vagal
activation which presumably slows down the conduction
of the atrioventricular node, consequently lowering the
heart rate [41].
The Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) trial showed that digoxin
(used without beta-blockers or non-dihydropyridine
calcium channel blockers) achieved rate control (rest
≤80 beats/min) in 58% of the patients given digoxin as
first therapy [42].
Other medical interventions
Beta-blockers (Vaughan Williams class II) block the
sympathetic activity in the atrioventricular node, conse-
quently decreasing the heart rate [41]. The different
beta-blockers are illustrated in Table 2. Beta-blocker
monotherapy is often the recommended first-line ther-
apy for heart rate control in atrial fibrillation and atrial
flutter [43]. The AFFIRM trial showed that beta-blockers
(with or without digoxin) achieved rate control (rest
≤80 beats/min) in 70% of the patients given beta-
blockers as first therapy [42].
Non-dihydropyridine calcium channel blockers (Vaughan
Williams class IV) slow the atrioventricular node
conduction by blocking calcium channels and thus lower
the heart rate [41]. The main non-dihydropyridine calcium
channel blockers are illustrated in Table 2. Non-
dihydropyridine calcium channel blockers are reasonable in
controlling the heart rate [44] but are not recommended in
patients with concomitant heart failure because of their
negative inotropic effects [45]. The AFFIRM trial showed
that non-dihydropyridine calcium channel blockers (with
or without digoxin achieved rate control (rest ≤80 beats/
min) in 54% of the patients given non-dihydropyridine cal-
cium channel blockers as first therapy [42].
Amiodarone (Vaughan Williams class III) may also
control the heart rate, as it exhibits beta and calcium
channel blockade in addition to its antiarrhythmic activ-
ity. However, amiodarone has extensive non-cardiac ad-
verse events and is only used if other rate control drugs
are not effective enough, not well tolerated, or contrain-
dicated [16].
Sotalol (Vaughan Williams class III) may also control
the heart rate, as it exhibits beta blockade in addition to
its antiarrhythmic activity. However, sotalol may induce
life-threatening arrhythmias such as torsades de pointes
[46]. Accordingly, it is seldom used.
Why is it important to do this review?
Digoxin is widely used for heart rate control in patients
with atrial fibrillation and atrial flutter. Guidelines
recommend using digoxin as the primary drug for heart
rate control in patients with atrial fibrillation and atrial
flutter who have concomitant heart failure and reduced
ejection fraction [16, 43, 47]. Digoxin is also recom-
mended for acute heart rate control in patients with pre-
served ejection fraction [16, 43, 47]. Nevertheless, a
report from 2014 has shown a dramatic decrease in
overall digoxin treatment visits in the USA, from 12.9
million visits in 1997 to 1.87 million visits in 2012 [48].
According to the newest guideline by the European
Society of Cardiology, there are no head-to-head rando-
mised trials of digoxin versus other medical interven-
tions in relation to heart rate control in patients with
atrial fibrillation or atrial flutter [43]. However, our
group found several randomised trials by performing a
preliminary search in Medical Literature Analysis and
Retrieval System Online (MEDLINE) [49–52]. Siu et al.
compared diltiazem, digoxin, and amiodarone and
showed superior rate control in the diltiazem group [49].
Joseph et al. compared sotalol, amiodarone, and digoxin
and showed superior rate control in the sotalol group
[50]. Tisdale et al. compared diltiazem with digoxin
and showed superior rate control in the diltiazem
group [51]. Tse et al. compared digoxin with amioda-
rone and showed similar rate control efficacy in the
compared groups [52].
Table 2 The Vaughan Williams classification
Class Mechanism Examples
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During recent years, systematic reviews of observa-
tional studies have compared digoxin versus no digoxin
(the latter participants usually receiving some other
treatment for heart rate control) in patients with atrial
fibrillation or atrial flutter and showed that digoxin
seemed to increase the risk of all-cause mortality regard-
less of concomitant heart failure [53–56]. A systematic
review of both observational studies and randomised
clinical trials showed similar findings on all-cause mor-
tality when assessing the observational studies. However,
they did not show any difference on all-cause mortality
when assessing the randomised clinical trials. They
reported that the observed association between digoxin
and mortality in observational studies might be a result
of confounding that cannot be mitigated by statistical
adjustment [57].
In 2014, a systematic review of randomised trials
assessed the drugs used for heart rate control and
included 16 randomised clinical trials. Eight of them
were head-to-head trials comparing digoxin with other
medical heart rate control interventions. The authors
reported that the data were inconclusive as to whether
any one drug was safer or more effective than the others.
However, the review authors did not use any method to
deal with risks of random errors [58]. Therefore, it is still
unclear whether digoxin offers more benefits and less
harms compared with placebo, no intervention, or with
other medical interventions in controlling the heart rate.
No former systematic review comparing digoxin with
placebo, no intervention, or with other medical interven-
tions for atrial fibrillation and atrial flutter has taken
account both risks of systematic errors and risks of ran-
dom errors (Cochrane methodology, Trial Sequential
Analysis, and the Grades of Recommendation, Assess-
ment, Development, and Evaluation (GRADE) assess-
ment). In the present systematic review, we will collect
and present current evidence of digoxin versus placebo,
no intervention, or with other medical interventions for
atrial fibrillation and atrial flutter.
Objectives
This review has two objectives:
1. To assess the beneficial and harmful effects of
digoxin compared with placebo or no intervention
for atrial fibrillation and atrial flutter
2. To assess the beneficial and harmful effects of
digoxin compared with other medical interventions
for atrial fibrillation and atrial flutter
Methods
This systematic review protocol has been developed
based on Preferred Reporting Items for Systematic
Reviews and Meta-Analysis Protocols (PRISMA-P)
guidelines for reporting systematic reviews evaluating
healthcare interventions [59, 60]. A PRISMA-P checklist
file is attached (Additional file 1).
Criteria for considering studies for this review
Types of studies
Randomised clinical trials irrespective of trial design, set-
ting, publication status, publication year, and language.
We will not specifically search for non-randomised stud-
ies. However, if we during our literature searches identify
non-randomised studies (quasi-randomised studies or
observational studies) with adequate reports of harmful
effects, then we will narratively report these results. By
focusing on randomised clinical trials, we are aware that
the present review will be biased towards focusing on
benefits and less on harms. Trials that only include a
subset of eligible participants will only be included if (1)
separate data on the eligible participants are available or
(2) the majority of participants are eligible. We will
document difficult decisions in the review, and sensitiv-
ity analyses will assess the impact of these decisions on
the findings of the review. Randomised clinical trials will
be included irrespective of the reporting of one of the
outcomes in this protocol.
Types of participants
Patients with atrial fibrillation or atrial flutter. We will
accept the definitions used by the trialists. Patients will
be included irrespective of age, sex, and comorbidities.
Types of interventions
We will include four types of trials:
 Digoxin compared with placebo
 Digoxin compared with no intervention
 Digoxin added to a co-intervention compared with a
similar co-intervention
 Digoxin compared with any type of medical
intervention other than digoxin (e.g. beta-blockers,
non-dihydropyridine calcium channel blockers, ami-
odarone, or sotalol)
We will as experimental intervention accept digoxin
irrespective of dose, route of administration, and dur-
ation of administration.
All control interventions will be included irrespective
of dose, route of administration, and duration.
We will accept any type of co-intervention when such
co-intervention is intended to be delivered similar to the
experimental and the control group (i.e. we will exclude
trials that, e.g. add a beta-blocker to the experimental
group and not to the control group).
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Types of outcome measures
We will for all outcomes, beside heart rate control and
conversion to sinus rhythm, use the trial results at
maximal follow-up. We will for heart rate control and
conversion to sinus rhythm use the trial results reported
within 48 h to assess the acute effects of digoxin versus
placebo, no intervention, or other medical interventions
in patients with atrial fibrillation or atrial flutter. We
will, additionally, conduct sensitivity analyses excluding
all trials with short (less than 12 months) or long (more
than 24 months) follow-up in the primary meta-analyses
of the outcome results at maximal follow-up (i.e. all-
cause mortality, serious adverse events, quality of life,
heart failure, and stroke).
Primary outcomes
1. All-cause mortality.
2. Serious adverse events. We will define a serious
adverse event as any untoward medical occurrence
that resulted in death, was life-threatening, required
hospitalisation or prolongation of existing hospital-
isation, and resulted in persistent or significant
disability or jeopardised the patient [61].
3. Quality of life measured on any valid scale.
Secondary outcomes
1. Heart failure (as defined by the trialists)
2. Stroke (as defined by the trialists)
3. Heart rate control
4. Conversion to sinus rhythm (as defined by the
trialists)
All outcomes, except quality of life and heart rate
control, will be analysed as proportions of participants
in each group.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE, EMBASE,
LILACS, Science Citation Index Expanded on Web of
Science, and BIOSIS in order to identify relevant trials.
The preliminary search strategy for MEDLINE (Ovid) is
given in Additional file 2.
We will search all databases from their inception to
the present, and we will impose no restriction on
language of publication or publication status.
Searching other resources
The reference lists of relevant publications will be
checked for any unidentified randomised trials. We will
contact authors of included studies, and major
pharmaceutical companies, by email asking for unpub-
lished randomised trials. Further, we will search for
ongoing trials on:
 ClinicalTrials.gov (www.clinicaltrials.gov);
 Google Scholar (https://scholar.google.dk/);
 The Turning Research into Practice (TRIP) Database
(https://ww.tripdatabase.com/);
 European Medicines Agency (EMA) (http://
www.ema.europa.eu/ema/);
 United States Food and Drug Administration (FDA)
(www.fda.gov);
 China Food and Drug Administration (CFDA)
(http://eng.sfda.gov.cn/WS03/CL0755/);





 The World Health Organization (WHO)
International Clinical Trials Registry Platform
(ICTRP) search portal (http://apps.who.int/
trialsearch/).
Additionally, we will hand search conference abstracts
from cardiology conferences for relevant trials.
We will also include unpublished and grey literature
trials if we identify these, and assess relevant retraction
statements and errata for included studies.
Data collection and analysis
We will perform the review following the recommenda-
tions of Cochrane [62]. The analyses will be performed
using Review Manager 5.3 [63] and Trial Sequential
Analysis ver. 0.0.5.5 beta [64]. In case of Review Man-
ager statistical software not being sufficient, we will use
STATA 14 [65].
Selection of studies
Two authors (NJS and SS) will independently screen
titles and abstracts. We will retrieve all relevant full-text
study reports/publications, and two review authors (NJS
and SS) will independently screen the full-text and iden-
tify and record reasons for exclusion of the ineligible
studies. We will resolve any disagreement through
discussion, or if required, we will consult a third person
(JCJ). Trial selection will be displayed in an adapted flow
diagram as per the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) state-
ment [66].
Data extraction and management
Four authors (NJS, SS, EEN, and JF) will extract data
independently from the included trials. Disagreements
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will be resolved by discussion with a fifth author (JCJ).
We will assess duplicate publications and companion pa-
pers of a trial together in order to evaluate all available
data simultaneously (maximise data extraction, correct
bias assessment). We will contact the trial authors by
email to specify any additional data, which may not have
been reported sufficiently or at all in the publication.
Trial characteristics
Bias risk components (as defined below); trial design
(parallel, factorial, or crossover); number of intervention
arms; length of follow-up; estimation of sample size;
inclusion and exclusion criteria.
Participants’ characteristics and diagnosis
Number of randomised participants; number of analysed
participants; number of participants lost to follow-up/
withdrawals/crossover; compliance with medication; age
range (mean or median) and sex ratio; type of
arrhythmia (atrial fibrillation or atrial flutter); baseline
numbers of cardiovascular risk factors (i.e. diabetes mel-
litus, hypertension, hyperlipidaemia, or smoking); base-
line number of participants with heart failure; baseline
number of participants with valvular heart disease; base-
line number of participants with previous myocardial in-
farction; baseline number of participants with previous
revascularisation; and baseline number of participants
with previous angina.
Intervention characteristics
Dose of intervention, duration of intervention, and mode
of administration.
Control characteristics
Type of control intervention, dose of intervention,
duration of intervention, and mode of administration.
Co-intervention characteristics
Type of co-intervention, dose of co-intervention, dur-
ation of co-intervention, and mode of administration.
Outcomes
All outcomes listed above will be extracted from each
randomised clinical trial, and we will identify if out-
comes are incomplete or selectively reported according
to the criteria described later in ‘incomplete outcome
data’ bias domain and ‘selective outcome reporting’ bias
domain.
Notes
Funding of the trial and notable conflicts of interest of
trial authors will be extracted, if available.
We will note in the ‘Characteristics of included stud-
ies’ table if outcome data were not reported in a usable
way. Two review authors (NJS and SS) will independ-
ently transfer data into the Review Manager file [63].
Disagreements will be resolved through discussion, or if
required, we will consult with a third author (JCJ).
Assessment of risk of bias in included studies
We will use the instructions given in the Cochrane
Handbook for Systematic Reviews of Interventions [62]
in our evaluation of the methodology and hence the risk
of bias of the included trials. We will evaluate the meth-
odology in respect of:
 Random sequence generation
 Allocation concealment
 Blinding of participants and personnel
 Blinding of outcome assessment
 Incomplete outcome data
 Selective outcome reporting
 Other risks of bias
 Overall risk of bias
These domains enable classification of randomised
trials with low risk of bias and high risk of bias. The
latter trials tend to overestimate positive intervention
effects (benefits) and underestimate negative effects
(harms) [67–73].
We will classify the trials according to the following
criteria:
Random sequence generation
 Low risk: If sequence generation was achieved using
computer random number generator or a random
number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice were also considered
adequate if performed by an independent
adjudicator.
 Unclear risk: If the method of randomisation was
not specified, but the trial was still presented as
being randomised.
 High risk: If the allocation sequence is not
randomised or only quasi-randomised. These trials
will be excluded.
Allocation concealment
 Low risk: If the allocation of patients was performed
by a central independent unit, on-site locked com-
puter, identical-looking numbered sealed envelopes,
drug bottles, or containers prepared by an independ-
ent pharmacist or investigator.
 Uncertain risk: If the trial was classified as
randomised but the allocation concealment process
was not described.
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 High risk: If the allocation sequence was familiar to
the investigators who assigned participants.
Blinding of participants and personnel
 Low risk: If the participants and the personnel were
blinded to intervention allocation and this was
described.
 Uncertain risk: If the procedure of blinding was
insufficiently described.
 High risk: If blinding of participants and the
personnel was not performed.
Blinding of outcome assessment
 Low risk of bias: If it was mentioned that outcome
assessors were blinded and this was described.
 Uncertain risk of bias: If it was not mentioned if the
outcome assessors in the trial were blinded, or the
extent of blinding was insufficiently described.
 High risk of bias: If no blinding or incomplete
blinding of outcome assessors was performed.
Incomplete outcome data
 Low risk of bias: If missing data were unlikely to
make treatment effects depart from plausible values.
This could either be (1) there were no drop-outs or
withdrawals for all outcomes or (2) the numbers and
reasons for the withdrawals and drop-outs for all
outcomes were clearly stated and could be described
as being similar to both groups. Generally, the trial
is judged as at a low risk of bias due to incomplete
outcome data if drop-outs are less than 5%. How-
ever, the 5% cut-off is not definitive.
 Uncertain risk of bias: If there was insufficient
information to assess whether missing data were
likely to induce bias on the results.
 High risk of bias: If the results were likely to be
biased due to missing data either because the
pattern of drop-outs could be described as being dif-
ferent in the two intervention groups or the trial
used improper methods in dealing with the missing
data (e.g. last observation carried forward).
Selective outcome reporting
 Low risk of bias: If a protocol was published before
or at the time the trial was begun and the outcomes
specified in the protocol were reported on. If there
is no protocol or the protocol was published after
the trial has begun, reporting of all-cause mortality
and serious adverse events will grant the trial a grade
of low risk of bias.
 Uncertain risk of bias: If no protocol was published
and the outcomes all-cause mortality and serious
adverse events were not reported on.
 High risk of bias: If the outcomes in the protocol
were not reported on.
Other risks of bias
 Low risk of bias: If the trial appears to be free of
other components (for example, academic bias or
for-profit bias) that could put it at risk of bias.
 Unclear risk of bias: If the trial may or may not be
free of other components that could put it at risk of
bias.
 High risk of bias: If there are other factors in the
trial that could put it at risk of bias (for example,
authors conducted trials on the same topic, for-
profit bias, etc.).
Overall risk of bias
 Low risk of bias: The trial will be classified as overall
‘low risk of bias’ only if all of the bias domains
described in the above paragraphs are classified as
‘low risk of bias’.
 High risk of bias: The trial will be classified ‘high
risk of bias’ if any of the bias risk domains described
in the above are classified as ‘unclear’ or ‘high risk of
bias’.
We will assess the domains ‘blinding of outcome
assessment’, ‘incomplete outcome data’, and ‘selective out-
come reporting’ for each outcome result. Thus, we will
assess the bias risk for each outcome assessed in
addition to each trial. Our primary conclusions will be
based on the results of both our primary and secondary
outcome results with overall low risk of bias. If no
results with overall low risk of bias are found, we will
base our primary conclusions on the outcome results
irrespective of overall risk of bias. We will present our
primary conclusions in the ‘Summary of Findings’ table.
Differences between the protocol and the review
We will conduct the review according to this published
protocol and report any deviations from it in the ‘Differ-
ences between the protocol and the review’ section of
the systematic review.
Measures of treatment effect
Dichotomous outcomes We will calculate risk ratios
(RRs) with 95% confidence interval (CI) for dichotomous
outcomes. We will also report Trial Sequential Analysis-
adjusted CIs (see paragraphs below).
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Continuous outcomes We will calculate the mean dif-
ferences (MDs) and if necessary, as a hypothesis generat-
ing analysis, the standardised mean difference (SMD)
with 95% CI for continuous outcomes. We will also
report Trial Sequential Analysis-adjusted CIs (see para-
graphs below).
Dealing with missing data
We will, as first option, contact all trial authors to obtain
any relevant missing information and data (i.e. for data
extraction and for assessment of risk of bias, as specified
above).
Dichotomous outcomes We will not impute missing
values for any outcomes in our primary analysis. In two
of our sensitivity analyses (see paragraph below), we will
impute data.
Continuous outcomes We will primarily analyse scores
assessed at single time points. If only change from base-
line scores are reported, we will analyse the results to-
gether with follow-up scores [62]. If standard deviations
(SDs) are not reported, we will calculate the SDs using
trial data, if possible. We will not use intention-to-treat
data if the original report did not contain such data. We
will not impute missing values for any outcomes in our
primary analysis. In our sensitivity analysis (see para-
graph below) for continuous outcomes, we will impute
data.
Assessment of heterogeneity
We will primarily investigate forest plots to visually
assess any sign of heterogeneity. We will secondly assess
the presence of statistical heterogeneity by chi2 test
(threshold P < 0.10) and measure the quantities of het-
erogeneity by the I2-statistic [74, 75].
We will follow the recommendations for threshold by
the Cochrane Handbook for Systemic Reviews of Interven-
tions [62]:
 0 to 40%: might not be important
 30 to 60%: may represent moderate heterogeneity
 50 to 90%: may represent substantial heterogeneity
 75 to 100%: may represent considerable
heterogeneity
We will investigate possible heterogeneity through
subgroup analyses. Ultimately, we may decide that a
meta-analysis should be avoided [62].
Assessment of reporting biases
We will use a funnel plot to assess reporting bias if ten
or more trials are included. We will visually inspect fun-
nel plots to assess the risk of bias. We are aware of the
limitations of a funnel plot, i.e. a funnel plot assesses
bias due to small sample size and asymmetry of a funnel
plot is not necessarily caused by reporting bias. From
this information, we assess possible reporting bias. For
dichotomous outcomes, we will test asymmetry with the
Harbord test [76] if τ2 is less than 0.1 and with the
Rücker test if τ2 is more than 0.1. For continuous out-
comes, we will use the regression asymmetry test [77]
and the adjusted rank correlation [78].
Unit of analysis issues
We will only include randomised clinical trials. For trials
using crossover design, only data from the first period
will be included [62, 79]. There will therefore not be any
unit of analysis issues. We will not include cluster ran-
domised trials, as these have a high risk of biased results
due to confounding [62].
Data synthesis
Meta-analysis
We will undertake this meta-analysis according to the
recommendations stated in the Cochrane Handbook for
Systematic Reviews of Interventions [62], Keus et al. [80],
and the eight-step assessment suggested by Jakobsen et
al. for better validation of meta-analytic results in sys-
tematic reviews [81]. We will use the statistical software
Review Manager 5.3 [63] provided by Cochrane to
analyse data.
We will assess our intervention effects with both ran-
dom effects meta-analyses [82] and fixed effects meta-
analyses [83]. We will use the more conservative point
estimate of the two [81]. The more conservative point
estimate is the estimate closest to zero effect. If the two
estimates are similar, we will use the estimate with the
widest CI. We will conduct sensitivity analyses and sub-
group analyses to explore the reasons for substantial
statistical heterogeneity (see the ‘Assessment of hetero-
geneity’ section). We will assess the risk of publication
bias in meta-analyses consisting of ten trials or more by
visually inspection of forest plots and statistical tests for
funnel plot asymmetry (see the ‘Assessment of reporting
biases’ section). We adjust our thresholds for statistical
significance due to problems with multiplicity (family-
wise error rate) by dividing the prespecified P value
threshold with the value halfway between 1 (no adjust-
ment) and the number of primary or secondary outcome
comparisons (Bonferroni adjustment) [81, 84]. We use
three primary outcomes, and therefore, we will consider
a P value of 0.025 or less as the threshold for statistical
significance for these outcomes [81]. We use four sec-
ondary outcomes, and therefore, we will consider a P
value of 0.02 or less as threshold for statistical signifi-
cance for these outcomes [81]. We will use the eight-
step procedure to assess if the thresholds for significance
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are crossed [81]. Our primary conclusion will be based
on results with low risk of bias [81].
Where multiple trial intervention groups are reported
in a single trial, we will include only the relevant groups.
If two comparisons are combined in the same meta-
analysis, we will halve the control group to avoid
double-counting [81, 85].
Trials with a factorial design will be included. In case
of, e.g. a 2 × 2 factorial designed trial, the two groups
receiving digoxin will be considered experimental
groups, while the two groups receiving other medical
rate control interventions will be considered control
groups.
If quantitative synthesis is not appropriate, we will
report the results in a narrative way.
Trial Sequential Analysis
Cumulative meta-analyses are at risk of producing ran-
dom errors due to sparse data and multiple testing of ac-
cumulating data [64, 85–94]. Therefore, Trial Sequential
Analysis [64] can be applied to control these risks
(http://www.ctu.dk/tsa/) [91]. Similar to a sample size
calculation in a randomised clinical trial, Trial Sequential
Analysis estimates the required information size (that is
the number of participants needed in a meta-analysis to
detect or reject a certain intervention effect) in order to
minimise random errors [89]. The required information
size takes into account the anticipated intervention
effect, the variance of the anticipated difference in inter-
vention effects, the acceptable risk of falsely rejecting
the null hypothesis (alpha), the acceptable risk of falsely
confirming the null hypothesis (beta), and the vari-
ance of the intervention effect estimated between tri-
als [81, 89, 95]. We tried to base the anticipated
intervention effects on empirical data [81]. However,
no suitable empirical data could be found, and in-
stead, we pragmatically hypothesised the anticipated
intervention effects. When analysing dichotomous
outcomes, we pragmatically anticipated an interven-
tion effect of 15% relative risk reduction. When
analysing continuous outcomes, we pragmatically
anticipated an intervention effect equal to the mean
difference of the observed SD/2 [96].
Trial Sequential Analysis enables testing for signifi-
cance to be conducted each time a new trial is included
in the meta-analysis. On the basis of the required infor-
mation size, trial sequential monitoring boundaries are
constructed. This enables one to determine the statistical
inference concerning cumulative meta-analysis that has
not yet reached the diversity-adjusted required informa-
tion size [86, 89].
Firm evidence for benefit or harm may be established if
a trial sequential monitoring boundary is crossed before
reaching the diversity-adjusted required information size,
in which case further trials may turn out to be superflu-
ous. In contrast, if a boundary is not surpassed, one may
conclude that it is necessary to continue with further trials
before a certain intervention effect can be detected or
rejected. Firm evidence for lack of the postulated interven-
tion effect can also be assessed with Trial Sequential Ana-
lysis. This occurs when the cumulative Z-score crosses the
trial sequential boundaries for futility.
For dichotomous outcomes, we will estimate the
required information size based on a relative risk reduc-
tion of 15%, the observed proportion of participants with
an outcome in the control group, an alpha of 2.5% for
our primary outcomes and 2.0% for our secondary out-
comes (see the ‘Meta-analysis’ section), a beta of 10%,
and diversity as suggested by the trials in the meta-
analysis (diversity-adjusted required information size)
[81, 89]. Additionally, we will calculate Trial Sequential
Analysis-adjusted CIs.
For continuous outcomes, we will estimate the required
information size based on a minimal clinically important
difference of SD/2, the standard deviation observed in the
control group, an alpha of 2.5% for our primary outcomes
and 2.0% for our secondary outcomes (see ‘Meta-ana-
lysis’), a beta of 10%, and a diversity as suggested by the
trials in the meta-analysis (diversity adjusted required in-
formation size) [81, 89]. Additionally, we will calculate
Trial Sequential Analysis-adjusted CIs.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis
We will perform the following subgroup analyses when
analysing the primary outcomes (all-cause mortality,
serious adverse event, and quality of life).
1. High risk of bias trials compared to low risk of bias
trials
2. Comparison of different types of control
interventions
3. Participants with atrial fibrillation compared to
participants with atrial flutter
4. Age of participants: 0 to 59 years, 60 to 79 years,
and above 80 years
5. Duration of atrial fibrillation: recent-onset atrial
fibrillation (as defined by the trialists), paroxysmal
atrial fibrillation (less than 7 days of onset), persist-
ent atrial fibrillation (more than 7 days and less than
1 year of onset), and long-standing persistent atrial
fibrillation (more than 1 year of onset).
6. Men compared to women
7. Participants with heart failure compared to
participants without heart failure
8. Comparison of trials with different medical co-
intervention
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We will use the formal test for subgroup differences in
Review Manager [63].
Sensitivity analysis
To assess the potential impact of the missing data for
dichotomous outcomes, we will perform the two follow-
ing sensitivity analyses on both the primary and second-
ary outcomes.
 ‘Best-worst-case’ scenario: We will assume that all
participants lost to follow-up in the experimental
group have survived, had no serious adverse event,
had no heart failure, had no stroke, and converted
to sinus rhythm and that all those participants lost
to follow-up in the control group have not survived,
had a serious adverse event, had a heart failure, had
a stroke, and did not convert to sinus rhythm.
 ‘Worst-best-case’ scenario: We will assume that all
participants lost to follow-up in the experimental
group have not survived, had a serious adverse
event, had a heart failure, had a stroke, and did not
convert to sinus rhythm and that all those partici-
pants lost to follow-up in the control group have
survived, had no serious adverse event, had no heart
failure, had no stroke, and converted to sinus
rhythm.
We will present results of both scenarios in our
review.
When analysing quality of life or heart rate control, a
‘beneficial outcome’ will be the group mean plus two
standard deviations (SDs) (we will secondly use one SD
in another sensitivity analysis) of the group mean and a
‘harmful outcome’ will be the group mean minus two
SDs (we will secondly use one SD in another sensitivity
analysis) of the group mean [81].
To assess the potential impact of missing SDs for con-
tinuous outcomes, we will perform the following sensi-
tivity analysis.
 Where SDs are missing and it is not possible to
calculate them, we will impute SDs from trials with
similar populations and low risk of bias. If we find
no such trials, we will impute SDs from trials with a
similar population.
We will present results of this scenario in our review.
Other post hoc sensitivity analyses might be warranted
if unexpected clinical or statistical heterogeneity is iden-
tified during the analysis of the review results [81].
‘Summary of Findings’ table
We will create a ‘Summary of Findings’ table using each
of the prespecified primary and secondary outcomes
(all-cause mortality, serious adverse event, quality of life,
stroke, heart failure, heart rate control, and conversion
to sinus rhythm). We will use the five GRADE consider-
ations (bias risk of the trials, consistency of effect, im-
precision, indirectness, and publication bias) to assess
the quality of a body of evidence as it relates to the stud-
ies which contribute data to the meta-analyses for the
prespecified outcomes [81, 97–99]. We will use methods
and recommendations described in Chapter 8 (Section
8.5) and Chapter 12 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions [62] using GRADEpro
software. We will justify all decisions to downgrade the
quality of studies using footnotes, and we will make
comments to aid the reader’s understanding of the
review where necessary. Firstly, we will present our
results in the ‘Summary of Findings’ table based on the
results from the trials with low risk of bias; secondly, we
will present the results based on all trials.
Discussion
Observational evidence has indicated that digoxin might
increase the risk of serious adverse events in patients
with atrial fibrillation—on the other hand, digoxin is a
recommended and commonly used intervention. More-
over, clinical guidelines postulate that no head-to-head
randomised clinical trials of digoxin versus other med-
ical interventions in relation to heart rate control in pa-
tients with atrial fibrillation or atrial flutter exists—still,
we can identify several trials on the topic by searching
PubMed. The present systematic review aims at compar-
ing digoxin with placebo, no intervention, or with other
medical interventions in patients with atrial fibrillation
and atrial flutter. The outcomes will be all-cause mortal-
ity, serious adverse events, quality of life, stroke, heart
failure, heart rate control, and conversion to sinus
rhythm. Due to the millions affected around the World,
there is an urgent need of this systematic review.
This protocol has a number of strengths. The prede-
fined methodology is based on the Cochrane Handbook
for Systematic Reviews of Interventions [62], the eight-
step assessment suggested by Jakobsen et al. [81], Trial
Sequential Analysis [64], and GRADE assessment [97–
99]. Hence, this protocol takes into account both risks of
systematic errors and risk of random errors.
Our protocol also has a number of limitations. The
primary limitation is that we in one of our analyses as
control intervention intend to meta-analyse digoxin
compared with all other types of medical interventions
for atrial fibrillation and atrial flutter. Hence, if the
different types of control interventions have different
effects compared with digoxin, the statistical heterogen-
eity might be considerable and meta-analysis of all trials
in one analysis might not be valid. The reason for this
meta-analysis of different control interventions is that
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we do not expect to identify many relevant randomised
clinical trials and we want to increase the statistical
power. We have predefined a number of subgroup ana-
lyses and sensitivity analyses to assess if the effects differ
between trials using different types of control interven-
tions, and we will thoroughly consider if it is valid to
perform meta-analysis of all included trials. A further
limitation is the large number of subgroup analyses
which increases the risk of a type 1 error. We have
adjusted our thresholds for significance according to the
number of primary outcomes, but we have also included
multiple subgroup analyses and assess all outcomes at
two time points. The large risk of type 1 error will be
taken into account when interpreting the results of the
review.
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